[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346518-105":59,"doc-detail-346518-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","liver-metastases-dampen-il18-driven-t-cell-activity-and-immunotherapy-responsiveness-in-colorectal-cancer","Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer","","Liver metastases (LMs) reduce benefit from immune checkpoint blockade (ICB), but the underlying mechanism has been unclear. In mismatch repair-deficient (MMR-d) patients treated with immunotherapy, the liver tumor microenvironment shows reduced Vδ1+ γδ T cells. Elevated systemic and intratumoral IL18 are linked to ICB success specifically in LM patients, while cancer cells secrete IL18 binding protein (IL18BP) to suppress IL-18–driven immunity. IL18BP blockade restores IFNγ-driven Vδ1+ tumor killing, defining the IL18/IL18BP/Vδ1+ axis as a therapeutic vulnerability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liver-metastases-dampen-il18-driven-t-cell-activity-and-immunotherapy-responsiveness-in-colorectal-cancer/346518/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liver-metastases-dampen-il18-driven-t-cell-activity-and-immunotherapy-responsiveness-in-colorectal-cancer/346518.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do liver metastases affect immune checkpoint blockade outcomes in MMR-d colorectal cancer?","Question",{"text":112,"@type":113},"Patients with liver metastases derive less benefit from immune checkpoint blockade, and the study links this reduced response to changes in liver immunity, including reduced Vδ1+ γδ T cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does IL18 play in Vδ1+ γδ T cells and ICB responsiveness?",{"text":117,"@type":113},"IL18 activates liver-derived Vδ1+ T cells and elevated systemic IL18 levels, with intratumoral IL18 expression, predicts ICB success selectively in patients with liver metastases.",{"name":119,"@type":110,"acceptedAnswer":120},"How do tumor cells counter IL18-driven antitumor immunity?",{"text":121,"@type":113},"Tumor cells secrete IL18 binding protein (IL18BP) to suppress IL-18–mediated immunity; blocking IL18BP restores Vδ1+ function and enhances IFNγ-driven tumor killing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346518,1790191048,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Article  \nLiver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer  \nAuthors  \nAllard W.J. van Renterghem,  \nMiguel Parra-Martinez, MaartjeWitsen, ..., Krijn K. Dijkstra, Leila Akkari,  \nEmile E. Voest  \nCorrespondence  \n[e.voest@nki.nl](e.voest@nki.nl)  \nIn brief  \nvan Renterghem et al. investigate the impact of liver metastases on immunity in MMR-d/MSI-hi patients treated with ICB. They show that IL18 activates liverderived Vδ1+ T cells and predicts ICB benefit selectively in LM patients. Tumor cells counteracted this response by secreting IL18BP; blockade of IL1BP restores Vδ1+-mediated tumor killing.  \n• IL18 drives anti-tumor activity of liver Vδ1+ T cells, not of gutderived counterparts  \n• IL18 expression predicts ICB benefit in LM patients, but not in non-LM patients  \n• Cancer cells secrete IL18BP to suppress IL-18 immunity; blockade restores Vδ1+ function  \nvan Renterghem et al., 2026, Cell Reports Medicine 7, 102579 February 17, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2025.102579](https://doi.org/10.1016/j.xcrm.2025.102579)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nLiver metastases dampen IL18-driven γδ  \nT cell activity and immunotherapy responsiveness in colorectal cancer  \nAllard W.J. van Renterghem,1,2 Miguel Parra-Martinez,1,2 Maartje Witsen,1,2 Karlijn Verkerk,1,2 Marit Steur,1,2 Laurien J. Zeverijn,1,2 Krijn K. Dijkstra,1,2 Leila Akkari,2,3 and Emile E. Voest1,2,4,*  \n1Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands  \n2Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands  \n3Division of Tumor Biology and Immunology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands  \n4Lead contact  \n*Correspondence: [e.voest@nki.nl](e.voest@nki.nl)[ ](e.voest@nki.nl)[https://doi.org/10.1016/j.xcrm.2025.102579](https://doi.org/10.1016/j.xcrm.2025.102579)  \nSUMMARY  \nPatients with liver metastases (LMs) derive less benefit from immune checkpoint blockade (ICB), yet the mechanism remains poorly understood. In the liver tumor microenvironment of patients with mismatch repair-deficient (MMR-d) cancers treated with immunotherapy, we observe a reduction of Vδ1+ γδ T cells. Hepatic Vδ1+ T cells express high levels of IFNγ at baseline compared to other organs. In patients with LMs, we identify elevated systemic IL18 levels compared to metastatic patients without LMs and find that its intratumoral expression is associated with ICB success exclusively in patients with LMs. While liver γδ T cells are specifically sensitive to IL18 stimulation ex vivo, cancer cells counteract IL18-driven immunity by secretion of IL18 binding protein (IL18BP) . Blockade of IL18BP enhances interferon (IFN) γ-driven immunity against organoids in vitro. Taken together, we identify the IL18/IL18BP/Vδ1+ axis as an important regulator of ICB response and a therapeutic vulnerability for patients with LMs of MMR-d tumors.  \nINTRODUCTION  \nThe liver is a frontline immunological barrier with a highly specialized immune microenvironment to prevent excessive inflammation against non-pathogenic food- and microbiome-derived antigens from the intestines.1–3 Hepatic tolerance mechanisms, such as diminished T cell priming, have been shown to impact autoimmune diseases, viral infections, and organ transplantation.4–6 However, the hepatic immunoregulatory mechanisms that control the balance between homeostatic tolerance and immunological control are poorly understood.7 ,8 Importantly, the liver is also one of the most frequent sites of cancer metastasis, with colorectal cancer (CRC) being one of the most common primary cancers that spreads to the liver.9 , 10  \nImmune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) and programmed death-ligand 1 (PDL1) has emerged as an effective therapy for patients with a variety of tumor types. However, accumulat","cbCaikUmn6A3gM09","https://ap.wps.com/l/cbCaikUmn6A3gM09","pdf",6320821,21,"English","# Summary\n## IL18, IL18BP, and Vδ1+ T cell activation\n# Summary\n## Clinical association with ICB response\n# Introduction\n## Liver immune microenvironment and tolerance\n## ICB and mismatch repair-deficient colorectal cancer\n## Role of γδ T cells in immunotherapy","[{\"question\":\"How do liver metastases affect immune checkpoint blockade outcomes in MMR-d colorectal cancer?\",\"answer\":\"Patients with liver metastases derive less benefit from immune checkpoint blockade, and the study links this reduced response to changes in liver immunity, including reduced Vδ1+ γδ T cells.\"},{\"question\":\"What role does IL18 play in Vδ1+ γδ T cells and ICB responsiveness?\",\"answer\":\"IL18 activates liver-derived Vδ1+ T cells and elevated systemic IL18 levels, with intratumoral IL18 expression, predicts ICB success selectively in patients with liver metastases.\"},{\"question\":\"How do tumor cells counter IL18-driven antitumor immunity?\",\"answer\":\"Tumor cells secrete IL18 binding protein (IL18BP) to suppress IL-18–mediated immunity; blocking IL18BP restores Vδ1+ function and enhances IFNγ-driven tumor killing.\"}]","Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer | PDF",1790061789,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe2451e567943048142dee84f197e458.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49160253a0c1aa0f02ca42103383f017.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5c45c1153ce5814c13b48efeeba0ea5.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bc36bc53820432180d67529d5ae51a2.webp",980,1272]